Compare Keysight Technologies Inc (KEYS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Tango Therapeutics Inc. — how do they compare? Keysight Technologies Inc trades at $347 (market cap $60.88B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: Keysight Technologies Inc is far larger — about 16.3× Tango Therapeutics Inc.'s market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 57 Days and Tango Therapeutics Inc. for 0 Days on average.
| KEYS | TNGX | |
|---|---|---|
Market Cap | $60.88B | $3.74B |
Volume | 1,470,178 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $387.90 | $32.90 |
52-Week Low | $162.19 | $7.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $61.02B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $370.22, down 1.98% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 surpassing the $2.48 estimate. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
The outlook remains positive with a consensus price target of $421.29, implying 13.8% upside. Risks include elevated valuation multiples, such as a P/E of 50.1, and supply constraints that may limit near-term revenue conversion despite strong order growth. The stock's performance will hinge on continued execution in high-growth segments like AI and 6G.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
